Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share STAR-0215 Phase 1a results in an encore presentation at the annual World Allergy Congress on Sunday, December 3 at 10:00am ICT in Bangkok, Thailand.
- Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share STAR-0215 Phase 1a results in an encore presentation at the annual World Allergy Congress on Sunday, December 3 at 10:00am ICT in Bangkok, Thailand.
- Chris Morabito, M.D., Chief Medical Officer at Astria Therapeutics, will present a poster titled, “Support for STAR-0215 Administered Every Three- or Six-Months for Hereditary Angioedema: Phase 1a Results,” at 10:00am ICT on December 3 in Convention Hall B, poster board number 246.